ART 001 - ArTec Biotech
Alternative Names: ART-001 - ArTec BiotechLatest Information Update: 01 Mar 2024
At a glance
- Originator ArTec Biotech
- Class Antineoplastics; Immunotherapies; Natural killer cell therapies
- Mechanism of Action Immunologic cytotoxicity; Natural killer cell replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Preclinical Cancer
Most Recent Events
- 22 Feb 2024 Preclinical development for Cancer in USA (Parenteral) (ArTec Biotech Pipeline, February 2024)